JAK2 and melanoma: However, less special drug for metastatic melanoma is approved for the first-line therapy [5–9].The Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway is overactivated in many human cancers, including melanoma [10,11].